Nav: Home

Natural tooth repair method, using Alzheimer's drug, could revolutionize dental treatments

January 09, 2017

A new method of stimulating the renewal of living stem cells in tooth pulp using an Alzheimer's drug has been discovered by a team of researchers at King's College London.

Following trauma or an infection, the inner, soft pulp of a tooth can become exposed and infected. In order to protect the tooth from infection, a thin band of dentine is naturally produced and this seals the tooth pulp, but it is insufficient to effectively repair large cavities.

Currently dentists use man-made cements or fillings, such as calcium and silicon-based products, to treat these larger cavities and fill holes in teeth. This cement remains in the tooth and fails to disintegrate, meaning that the normal mineral level of the tooth is never completely restored.

However, in a paper published today in Scientific Reports, scientists from the Dental Institute at King's College London have proven a way to stimulate the stem cells contained in the pulp of the tooth and generate new dentine - the mineralised material that protects the tooth - in large cavities, potentially reducing the need for fillings or cements.

The novel, biological approach could see teeth use their natural ability to repair large cavities rather than using cements or fillings, which are prone to infections and often need replacing a number of times. Indeed when fillings fail or infection occurs, dentists have to remove and fill an area that is larger than what is affected, and after multiple treatments the tooth may eventually need to be extracted.

As this new method encourages natural tooth repair, it could eliminate all of these issues, providing a more natural solution for patients.

Significantly, one of the small molecules used by the team to stimulate the renewal of the stem cells included Tideglusib, which has previously been used in clinical trials to treat neurological disorders including Alzheimer's disease. This presents a real opportunity to fast-track the treatment into practice.

Using biodegradable collagen sponges to deliver the treatment, the team applied low doses of small molecule glycogen synthase kinase (GSK-3) to the tooth. They found that the sponge degraded over time and that new dentine replaced it, leading to complete, natural repair. Collagen sponges are commercially-available and clinically-approved, again adding to the potential of the treatment's swift pick-up and use in dental clinics.

Lead author of the study, Professor Paul Sharpe from King's College London said: "The simplicity of our approach makes it ideal as a clinical dental product for the natural treatment of large cavities, by providing both pulp protection and restoring dentine.

"In addition, using a drug that has already been tested in clinical trials for Alzheimer's disease provides a real opportunity to get this dental treatment quickly into clinics."
-end-
Notes for Editors:

The paper 'Promotion of natural tooth repair by small molecule GSK3 antagonists' by Vitor Neves, Rebecca Babb, Dhivya Chandrasekaran and Paul T Sharpe will be published in Scientific Reports at 10am on Monday 9 January 2017: http://www.nature.com/articles/srep39654

Professor Paul Sharpe is the head of the Craniofacial Development and Stem Cell Biology Division at the King's College London Dental Institute.

The King's College London Dental Institute

King's College London Dental Institute is one of the foremost Dental Schools in the world. Recently ranked fourth in the world in dentistry by the QS World University Rankings 2016, and first in the UK, the Dental Institute aims to maximise impact on health and wellbeing by integrating excellence across four areas:
  • Education / teaching
  • World-class science
  • Clinical approaches
  • Patient care
The Faculty's international reputation attracts students and staff from across the globe. The largest dental academic centre in the UK, they teach over 700 undergraduate students, 140 graduate taught students, 300 distance learning students and 110 graduate research students.

The Dental Institute has over 85 academic staff and is organised into four research divisions: Craniofacial Development & Stem Cell Biology, Mucosal & Salivary Research, Tissue Engineering & Biophotonics and Population & Patient Health. The research divisions complement the teaching and clinical service initiatives.

As well as excellent research facilities the Dental Institute has internationally recognised education programmes. With highly skilled teachers and supervisors, there are exceptional facilities, including access to over 300,000 patients each year across the two world-famous hospitals, Guy's and St Thomas', for hands-on clinical training. They are one of the most comprehensive dental academic health science centres in Europe.

Further details of the Institute may be found on its website: http://www.kcl.ac.uk/dentistry

King's College London

Related Clinical Trials Articles:

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.
Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.
Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.
Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.
When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.
More Clinical Trials News and Clinical Trials Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...